Omega-3 EPA + DHA: The Dosing Most People Miss (Inflammation, Cognition, ApoB)
Most men dose omega-3 too low to matter. The therapeutic range, the omega-3 index target, ApoB effects, and how fish oil oxidation silently undermines half the supply.
In 2018, the REDUCE-IT trial reported a 25% reduction in major cardiovascular events from 4 grams of EPA daily in high-risk patients already on statins. The trial used icosapent ethyl — a purified EPA pharmaceutical — and the dose was the variable that mattered. Trials using lower doses or mixed EPA/DHA formulations had repeatedly failed to show cardiovascular benefit. The conclusion the field has slowly absorbed: dosage and form matter as much as the molecule itself. Most men taking 1g of fish oil daily are not undersupplemented in fish oil. They are correctly supplementing a therapy that requires 2–4 grams to produce the effect they expected.
The omega-3 story is a dosing story masquerading as a supplement story.
The Omega-3 Index Is the Real Biomarker
Bill Harris developed the omega-3 index in 2004 as a measure of red blood cell EPA + DHA content. Unlike serum tests (which fluctuate with the last meal), RBC membrane composition reflects 3–4 months of intake — the omega-3 equivalent of HbA1c.
Harris and colleagues (2021) analyzed 17 prospective cohort studies and found mortality risk decreased continuously as omega-3 index rose. The lowest mortality clustered above 8%; the highest mortality below 4%. The difference in all-cause mortality between the lowest and highest quintiles was approximately 13% over multi-year follow-up — comparable to the effect of smoking cessation.
The US population average sits at 4–5%. Japan, where fish consumption is dramatically higher, averages 8–10%. The gap is the supplementation opportunity. For a US adult eating typical Western diet plus 1g/day of fish oil, the omega-3 index typically reaches 6–7% — still below the protective threshold. Reaching 8%+ generally requires 2g/day or higher, sustained for 3+ months.
The index is the only relevant marker. Serum omega-3 fatty acid panels are nearly useless — they tell you what you ate yesterday, not what is incorporated into your membranes. OmegaQuant remains the most validated commercial test ($50, mailed finger-stick blood spot). The result drives the dosing decision.
EPA vs DHA: Different Molecules, Different Jobs
EPA and DHA are both 20+ carbon omega-3 fatty acids with multiple double bonds, but they occupy different biochemical roles.
EPA is the substrate for the specialized pro-resolving mediators (SPMs) — resolvins (E-series), protectins, and maresins. These lipid mediators are not just anti-inflammatory; they actively terminate inflammation, signaling immune cells to clear debris and return to baseline. EPA also competes with arachidonic acid for cyclooxygenase enzymes, shifting eicosanoid production from pro-inflammatory PGE2 toward less inflammatory PGE3.
DHA is structural. It comprises roughly 40% of the fatty acid content of neuronal membranes and 60% of retinal photoreceptor membranes. DHA's unique structure (six double bonds, highly flexible) creates membrane fluidity that supports neurotransmitter receptor function and visual signal transduction. Cognitive and visual outcomes are DHA-dependent in ways EPA cannot substitute for.
The trial evidence reflects this division. REDUCE-IT used pure EPA at 4g/day and showed cardiovascular event reduction. The companion STRENGTH trial used a mixed EPA + DHA formulation at similar total dose and showed no event reduction despite similar triglyceride lowering. The interpretation has been that DHA may partially offset EPA's anti-arrhythmic or anti-platelet effects, or that EPA is the active molecule for cardiac endpoints specifically.
For cognitive aging, the data points the other way. Yurko-Mauro and colleagues (2010) showed 900mg/day of DHA improved verbal memory in adults with mild cognitive concerns over 24 weeks. EPA-only formulations have not produced equivalent cognitive effects in trials.
The practical implication: an EPA-dominant formulation (2:1 or 3:1 EPA:DHA ratio) is rational for men prioritizing cardiovascular and inflammation outcomes. A balanced formulation (roughly 1:1) is rational for cognitive prioritization. Most over-the-counter products skew DHA-dominant or balanced — explicitly EPA-dominant products are less common and worth seeking.
The Inflammation Mechanism
Chronic low-grade inflammation drives the pathology underlying most age-related disease — atherosclerosis, insulin resistance, neurodegeneration, sarcopenia. The biomarker of choice for monitoring is hs-CRP; the upstream driver is largely dietary, with omega-6 to omega-3 ratio at the center.
Modern Western diets deliver an omega-6 to omega-3 ratio of approximately 15–20:1, driven by industrial seed oils (soybean, corn, sunflower) ubiquitous in processed food. Ancestral diets are estimated to have delivered ratios closer to 1:1 or 2:1. The excess omega-6 (specifically linoleic acid) feeds arachidonic acid synthesis, which feeds pro-inflammatory eicosanoid production.
Supplementing EPA + DHA shifts the membrane ratio without requiring complete dietary overhaul. The compounds incorporate into phospholipid bilayers within weeks, displacing arachidonic acid and shifting the eicosanoid balance. At 2–4g/day, hs-CRP typically drops 10–20% in elevated baseline patients within 90 days. The effect compounds with other inflammation interventions — see the inflammation reduction protocol for the complete stack.
ApoB and Triglyceride Effects
Skulas-Ray and colleagues (2019) summarized the cardiovascular lipid effects in an American Heart Association science advisory. The dose-response for triglyceride reduction is clean: 2g/day produces roughly 15% reduction; 4g/day produces roughly 25–30% reduction. These effects are reliable across trials and populations, and they appear within 4–6 weeks of consistent dosing.
ApoB effects are smaller but real. At 4g/day, ApoB reductions of 5–10% are typical — modest compared to statins but meaningful as part of a multi-modal protocol. The mechanism is primarily through reduced hepatic VLDL synthesis, which lowers downstream LDL particle number. For men using statins, omega-3 stacks additively rather than competing on the same pathway.
For men managing ApoB through diet and supplementation without prescription drugs, omega-3 sits alongside citrus bergamot, berberine, soluble fiber, and a lower-ApoB dietary framework. The expected additive effect across a full protocol can match low-dose statin therapy without prescription pharmacology.
LDL cholesterol response is variable. Some men see LDL increase modestly on high-dose omega-3 — typically a shift toward larger, less atherogenic LDL particles rather than an increase in total atherogenic burden. ApoB is the more relevant marker; LDL-C alone misleads in this context.
The Oxidation Problem
The omega-3 supplement industry has a quality problem the consumer market has not absorbed. Long-chain polyunsaturated fatty acids are highly susceptible to oxidation — each double bond is a target for free radical attack. The same property that makes EPA and DHA biologically active in membranes makes them chemically unstable in capsules.
Albert and colleagues (2015) tested commercial fish oil products in New Zealand and found 83% exceeded industry oxidation thresholds at point of sale. Subsequent testing in other markets (US, UK, Canada) has shown 30–60% failure rates depending on the cutoffs used. The implications are not theoretical. Oxidized fish oil delivers lipid peroxides into circulation, which are pro-inflammatory and pro-atherogenic — the opposite of the intended effect.
The visible signal of oxidation is the "fishy burp." Fresh, properly preserved fish oil should be near-tasteless or carry a mild marine note. Strong fishy reflux, bitter aftertaste, or rancid odor when capsules are cut open all indicate oxidation. A simple test: bite into a capsule. If it tastes strongly of fish, the product is partially rancid.
Quality screening priorities: IFOS (International Fish Oil Standards) third-party certification with publicly available certificates of analysis showing peroxide value, anisidine value, and total oxidation (TOTOX) numbers. Reputable brands publish per-batch COAs. Avoid products without third-party testing data.
Storage matters. Refrigerate liquid fish oil after opening. Store capsules in a cool, dark place. Heat and light accelerate oxidation in storage. Avoid car gloveboxes, bathroom counters, and kitchen windowsills.
Source: Fish vs Algae
Fish oil derives EPA + DHA from cold-water fatty fish — salmon, mackerel, sardines, anchovies. The fish themselves do not synthesize omega-3s; they accumulate them from eating algae and zooplankton. Algae-based omega-3 sources eliminate the middle step.
For DHA, algae oil is fully equivalent to fish oil — identical molecule, same absorption, same membrane incorporation. For EPA, algae sources are emerging but generally more expensive per gram. Schizochytrium and similar microalgae strains are the dominant commercial sources.
The case for algae oil rests on three factors: sustainability (overfishing concerns), contamination (heavy metals and persistent organic pollutants concentrate up the marine food chain — properly distilled fish oil removes these, but the concern is real), and dietary preference (vegetarians, vegans, fish-averse).
The case for fish oil rests on cost economics — particularly for EPA-dominant formulations — and the longer track record of clinical evidence. Both sources work. Quality and dose matter more than source.
Krill oil is a third option, with phospholipid-bound omega-3s that may absorb slightly better per gram. The economics rarely favor krill — the per-gram cost of EPA + DHA from krill is typically 3–5x fish oil, and the absorption advantage does not offset the price.
The Cognitive Aging Evidence
Yurko-Mauro and colleagues (2010) conducted the MIDAS trial — 485 adults aged 55+ with mild age-related cognitive concerns, randomized to 900mg DHA daily or placebo for 24 weeks. The DHA group improved verbal memory measurably; placebo showed no change. The effect size was modest but statistically and clinically meaningful — approximately equivalent to reversing the cognitive aging of 3–5 years.
The mechanism is structural. DHA composes a substantial fraction of synaptic membrane phospholipids. Synaptic plasticity — the foundation of learning and memory — depends on membrane fluidity, receptor function, and the dynamic remodeling of synaptic connections. DHA-deficient membranes function suboptimally on all three axes.
The MIDAS findings have not been universally replicated. The OmegAD trial (2006) and others have shown smaller or null effects on cognitive outcomes in already-progressing Alzheimer's disease — suggesting that DHA may be more useful for prevention or early intervention than treatment of established neurodegeneration. The window for benefit appears to be before measurable cognitive decline, not after.
For men prioritizing cognitive longevity, the case for DHA supplementation at 1g+ daily, starting in middle age (40s), is reasonable. The downside risk is minimal; the upside is plausible and supported by trial evidence. This pairs with broader longevity extension interventions targeting cognitive aging.
Most men taking 1g of fish oil daily are not undersupplemented in fish oil. They are correctly supplementing a therapy that requires 2–4 grams to produce the effect they expected.
Inflammation Resolution: The SPM Pathway
The traditional anti-inflammatory framing of omega-3s has been refined by the discovery of specialized pro-resolving mediators (SPMs) — bioactive molecules derived from EPA and DHA that actively terminate inflammation. Charles Serhan's lab at Harvard identified resolvins (E-series from EPA, D-series from DHA), protectins, and maresins beginning in the early 2000s. The framework changed how the field thinks about inflammation.
Inflammation is not a single switch that gets turned off; it is a coordinated process with active resolution phases. SPMs signal macrophages to switch from inflammatory to resolution-promoting phenotypes, clear apoptotic cells, and restore tissue homeostasis. Inadequate SPM production leads to chronic, unresolved inflammation — the substrate of most age-related disease.
EPA and DHA from supplementation feed SPM production. The downstream effects on hs-CRP and other inflammation markers reflect this resolution-promoting role, not just classical anti-inflammatory inhibition. The mechanism explains why omega-3 effects on inflammation often appear gradually (weeks to months) rather than acutely — building SPM-producing infrastructure takes time.
Direct SPM supplementation has emerged in the last few years (commercial products containing concentrated resolvins and related molecules). The evidence base is thin compared to whole omega-3s; for most men, adequate EPA + DHA dosing is the more rational starting point.
Triglyceride-to-HDL Ratio: The Underused Marker
While ApoB and omega-3 index dominate the cardiovascular conversation, the triglyceride-to-HDL ratio quietly captures metabolic dysfunction across multiple pathways. The ratio reflects insulin sensitivity (high triglycerides + low HDL = insulin resistance), VLDL production rates (which drive ApoB), and systemic inflammation. Optimal ratio sits under 2.0 (using mg/dL units in the US). Above 3.5, the ratio signals metabolic syndrome trajectory.
Omega-3 supplementation at 2–4g/day reliably moves this ratio downward — primarily through triglyceride reduction, with modest HDL increases in some men. Skulas-Ray and colleagues (2019) documented the magnitude: typical 25–30% triglyceride reduction at 4g/day, with HDL changes of +2 to +5 mg/dL.
The ratio also predicts cardiovascular events independent of LDL cholesterol. For men with normal LDL but elevated triglyceride-to-HDL ratio, omega-3 supplementation often produces more measurable cardiovascular risk improvement than statin therapy alone would.
Track this ratio alongside ApoB. The two markers describe overlapping but distinct dimensions of cardiovascular risk, and omega-3 affects both.
Source Sustainability and Contamination
The fish oil supply chain carries environmental and contamination considerations beyond the immediate quality question. Wild-caught anchovy, sardine, and menhaden — the small forage fish that dominate fish oil sourcing — sit relatively low in the marine food chain, which reduces heavy metal accumulation compared to larger predatory fish. Mercury, cadmium, and lead concentrations in properly distilled fish oil from these sources typically fall well below regulatory limits.
Persistent organic pollutants (PCBs, dioxins) are the more relevant concern. These compounds bioaccumulate in fatty tissue across decades and concentrate in the oil fraction during processing. Quality manufacturers use molecular distillation and other purification methods that reduce POPs to negligible levels — verified through third-party testing. Cheap fish oil without rigorous purification can carry meaningful POP loads.
For sustainability, the marine populations that dominate fish oil sourcing (Peruvian anchoveta, Atlantic menhaden) face fishery pressure that varies by region and year. Marine Stewardship Council (MSC) certification provides one signal of sustainability practices. Algae-based omega-3 sources avoid the fishery pressure question entirely — relevant for men whose ethical framework weights sustainability heavily.
The economic structure of the industry — high consumer demand, variable supply year-to-year — means that fish oil prices can fluctuate substantially. Strategic buying of larger quantities from verified suppliers during stable price periods can reduce per-gram costs meaningfully.
The Protocol
Phase 1: Baseline
Test omega-3 index (OmegaQuant, ~$50). Pull triglycerides, ApoB, hs-CRP. The combination establishes both where you start and which outcomes to track.
Phase 2: Dosing
For omega-3 index 4–6%: start at 2g/day combined EPA + DHA, split across two doses with food. For omega-3 index above 6% but below 8%: start at 1.5g/day to reach 8%+ within 90 days. For triglyceride or ApoB targeting: 3–4g/day combined, EPA-dominant formulation, with the highest meal of the day. For cognitive prioritization: 2g/day with at least 1g DHA, balanced or DHA-dominant formulation.
The clinical trials use 2–4g/day routinely. The 1g consumer dose came from older guidelines designed for general population recommendations, not therapeutic effect.
Phase 3: Quality Selection
IFOS certification or equivalent third-party verification. Public COA showing TOTOX under 26 (the IFOS limit; freshest products run under 15). Triglyceride form (rTG) over ethyl ester (EE) where possible — better absorption and oxidative stability, though more expensive. Avoid proprietary blends that obscure EPA and DHA dosing per capsule.
Phase 4: Retest and Adjust
Recheck omega-3 index at 90 days. Hitting 8%+ at current dose: maintain. Below 8%: increase dose by 1g/day and recheck at 6 months. Above 12%: reduce dose (the data on extreme high indices is sparse, and there is theoretical concern about bleeding risk).
Stacking
Pairs with vitamin D (omega-3s help with vitamin D function), magnesium glycinate, and within a broader longevity extension protocol. For men on blood thinners (warfarin, apixaban) or planning surgery, discuss timing with physician — omega-3s at 4g/day have mild anti-platelet effects that compound additively.
Skip if
Active bleeding disorder, planning surgery within 2 weeks (most surgeons request omega-3 cessation 1–2 weeks pre-op), severe shellfish allergy (most fish oil is processed to remove allergens but verify with manufacturer), or already on prescription EPA (Vascepa) — additional supplementation is unnecessary.
Key Takeaways
- Omega-3 index above 8% is the cardiovascular and mortality target — not a blood test most labs run, but the only relevant marker.
- Typical 1g/day dosing keeps most men under 8%. Therapeutic effect requires 2–4g/day combined EPA + DHA, sustained for 3+ months.
- EPA dominates cardiovascular and inflammation outcomes; DHA dominates cognitive and visual outcomes. Match the formulation to the target.
- Triglyceride reductions of 25–30% and ApoB reductions of 5–10% are reliable at 4g/day; the lipid effects stack with statins, berberine, and citrus bergamot.
- Oxidation is the silent quality problem — 30–60% of commercial fish oil exceeds oxidation limits at purchase. IFOS certification and stored properly are non-negotiable.
Want to know if your omega-3 index supports your cardiovascular goals? → Take the PrimalPrime Cardiovascular Assessment to get a personalized protocol.